Alexion Pharmaceuticals Profit Margin

The latest profit margin for ALXN is 10.89% as of March 2021. That compares with 44.83% in the prior-year period — down 75.7% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Alexion Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ALXN's profit margin moved from 44.83% to 10.89% — a 75.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Alexion Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, ALXN currently prints 10.89% for profit margin, while the sector average sits near 13.89%. That is roughly 21.6% below the sector mean. Large gaps often invite a closer look at Alexion Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Alexion Pharmaceuticals converts resources into returns. At 10.89%, ALXN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 44.83% in the prior-year period — down 75.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ALXN's profit margin (10.89%), review year-over-year change from 44.83%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.